ZA200101910B - Treatment of depression. - Google Patents
Treatment of depression. Download PDFInfo
- Publication number
- ZA200101910B ZA200101910B ZA200101910A ZA200101910A ZA200101910B ZA 200101910 B ZA200101910 B ZA 200101910B ZA 200101910 A ZA200101910 A ZA 200101910A ZA 200101910 A ZA200101910 A ZA 200101910A ZA 200101910 B ZA200101910 B ZA 200101910B
- Authority
- ZA
- South Africa
- Prior art keywords
- use according
- treatment
- day
- depression
- unit dose
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 23
- 208000020401 Depressive disease Diseases 0.000 title claims description 9
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 13
- 229930006000 Sucrose Natural products 0.000 description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 12
- 239000005720 sucrose Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 10
- 239000003982 sigma receptor ligand Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000007415 Anhedonia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000003236 psychic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108010085082 sigma receptors Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ZRYMMWAJAFUANM-INIZCTEOSA-N (7s)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5h-carbazole-1-carboxamide Chemical compound C1[C@@H](C(C)(C)O)CCC2=C1NC1=C2C(C2=C(C(=CC=C2)N2C(C3=CC=CC(F)=C3N(C)C2=O)=O)C)=C(F)C=C1C(N)=O ZRYMMWAJAFUANM-INIZCTEOSA-N 0.000 description 1
- IPEMCIBPDYCJLO-UHFFFAOYSA-N 5-[(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)methyl]-n-(2,4,6-trimethoxyphenyl)furan-2-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1NC(=O)C(O1)=CC=C1CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C IPEMCIBPDYCJLO-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- GUDVQJXODNJRIJ-CALCHBBNSA-N 9-[3-[(3S,5R)-3,5-dimethyl-1-piperazinyl]propyl]carbazole Chemical compound C1[C@@H](C)N[C@@H](C)CN1CCCN1C2=CC=CC=C2C2=CC=CC=C21 GUDVQJXODNJRIJ-CALCHBBNSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229940126279 Compound 14f Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000011962 Substance-induced mood disease Diseases 0.000 description 1
- 231100000395 Substance-induced mood disorder Toxicity 0.000 description 1
- 206010065604 Suicidal behaviour Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003496 anti-amnesic effect Effects 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 230000028436 dopamine uptake Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229950004933 rimcazole Drugs 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- XWAONOGAGZNUSF-UHFFFAOYSA-N siramesine Chemical compound C1=CC(F)=CC=C1N1C2=CC=CC=C2C(CCCCN2CCC3(CC2)C2=CC=CC=C2CO3)=C1 XWAONOGAGZNUSF-UHFFFAOYSA-N 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- -1 theophylline acetic acids Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199801163 | 1998-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200101910B true ZA200101910B (en) | 2001-09-11 |
Family
ID=8101704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200101910A ZA200101910B (en) | 1998-09-15 | 1999-09-14 | Treatment of depression. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6358966B2 (bg) |
| EP (1) | EP1121122A1 (bg) |
| JP (1) | JP2002524515A (bg) |
| KR (1) | KR20010075120A (bg) |
| CN (1) | CN1317969A (bg) |
| AR (1) | AR021805A1 (bg) |
| AU (1) | AU5617499A (bg) |
| BG (1) | BG105378A (bg) |
| BR (1) | BR9913964A (bg) |
| CA (1) | CA2343761A1 (bg) |
| CZ (1) | CZ2001946A3 (bg) |
| EA (1) | EA200100355A1 (bg) |
| HK (1) | HK1040922A1 (bg) |
| HR (1) | HRP20010191A2 (bg) |
| HU (1) | HUP0103568A3 (bg) |
| ID (1) | ID29414A (bg) |
| IL (1) | IL141880A0 (bg) |
| IS (1) | IS5873A (bg) |
| NO (1) | NO20011268L (bg) |
| PL (1) | PL346528A1 (bg) |
| SK (1) | SK3502001A3 (bg) |
| TR (1) | TR200100767T2 (bg) |
| WO (1) | WO2000015225A1 (bg) |
| YU (1) | YU18701A (bg) |
| ZA (1) | ZA200101910B (bg) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR030453A1 (es) * | 2000-08-15 | 2003-08-20 | Lundbeck & Co As H | Composicion farmaceutica con contenido de 1' [4-[1-(4-fluorofenil)-1h-indol-3-il]-1-butil] espiro [isobenzofuran-1 (3h), 4'-piperidina] |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| KR20010042502A (ko) * | 1998-04-07 | 2001-05-25 | 피터슨 존 메이달 | 공황 발작의 치료 |
-
1999
- 1999-09-14 HU HU0103568A patent/HUP0103568A3/hu unknown
- 1999-09-14 EP EP99942779A patent/EP1121122A1/en not_active Withdrawn
- 1999-09-14 CN CN99810945A patent/CN1317969A/zh active Pending
- 1999-09-14 ZA ZA200101910A patent/ZA200101910B/en unknown
- 1999-09-14 AR ARP990104606A patent/AR021805A1/es unknown
- 1999-09-14 EA EA200100355A patent/EA200100355A1/ru unknown
- 1999-09-14 YU YU18701A patent/YU18701A/sh unknown
- 1999-09-14 TR TR2001/00767T patent/TR200100767T2/xx unknown
- 1999-09-14 JP JP2000569809A patent/JP2002524515A/ja not_active Withdrawn
- 1999-09-14 BR BR9913964-2A patent/BR9913964A/pt not_active Application Discontinuation
- 1999-09-14 ID IDW20010847A patent/ID29414A/id unknown
- 1999-09-14 IL IL14188099A patent/IL141880A0/xx unknown
- 1999-09-14 CA CA002343761A patent/CA2343761A1/en not_active Abandoned
- 1999-09-14 WO PCT/DK1999/000482 patent/WO2000015225A1/en not_active Application Discontinuation
- 1999-09-14 KR KR1020017003328A patent/KR20010075120A/ko not_active Application Discontinuation
- 1999-09-14 CZ CZ2001946A patent/CZ2001946A3/cs unknown
- 1999-09-14 AU AU56174/99A patent/AU5617499A/en not_active Abandoned
- 1999-09-14 PL PL99346528A patent/PL346528A1/xx unknown
- 1999-09-14 SK SK350-2001A patent/SK3502001A3/sk unknown
-
2001
- 2001-02-28 IS IS5873A patent/IS5873A/is unknown
- 2001-03-13 NO NO20011268A patent/NO20011268L/no not_active Application Discontinuation
- 2001-03-15 US US09/809,470 patent/US6358966B2/en not_active Expired - Fee Related
- 2001-03-15 HR HR20010191A patent/HRP20010191A2/hr not_active Application Discontinuation
- 2001-03-23 BG BG105378A patent/BG105378A/bg unknown
-
2002
- 2002-04-10 HK HK02102706.9A patent/HK1040922A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK3502001A3 (en) | 2001-12-03 |
| IL141880A0 (en) | 2002-03-10 |
| BR9913964A (pt) | 2001-07-03 |
| US20010020027A1 (en) | 2001-09-06 |
| KR20010075120A (ko) | 2001-08-09 |
| EA200100355A1 (ru) | 2001-08-27 |
| TR200100767T2 (tr) | 2001-07-23 |
| BG105378A (bg) | 2001-12-29 |
| CA2343761A1 (en) | 2000-03-23 |
| US6358966B2 (en) | 2002-03-19 |
| CZ2001946A3 (cs) | 2001-09-12 |
| PL346528A1 (en) | 2002-02-11 |
| NO20011268L (no) | 2001-05-15 |
| EP1121122A1 (en) | 2001-08-08 |
| AU5617499A (en) | 2000-04-03 |
| HK1040922A1 (zh) | 2002-06-28 |
| AR021805A1 (es) | 2002-08-07 |
| IS5873A (is) | 2001-02-28 |
| CN1317969A (zh) | 2001-10-17 |
| WO2000015225A1 (en) | 2000-03-23 |
| ID29414A (id) | 2001-08-30 |
| HUP0103568A3 (en) | 2003-05-28 |
| NO20011268D0 (no) | 2001-03-13 |
| HRP20010191A2 (en) | 2002-04-30 |
| JP2002524515A (ja) | 2002-08-06 |
| YU18701A (sh) | 2003-07-07 |
| HUP0103568A2 (hu) | 2002-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7230015B2 (en) | Method of treating of demyelinating diseases or conditions | |
| JP2014525413A (ja) | 糖尿病および関連障害を治療するためのモルフィナン誘導体 | |
| JP2007529556A (ja) | 認知障害の処置に有用なアセチルコリンエステラーゼ阻害剤およびｎ−メチル−ｄ−アスパラギン酸拮抗剤 | |
| JPH04226917A (ja) | 神経退化過程における予防及び治療用医薬 | |
| JP2019023202A (ja) | Ｌｓｄ１阻害剤を用いて多発性硬化症を処置する方法 | |
| JP2017534613A (ja) | デクスメデトミジン製剤を使用する睡眠障害の予防または治療 | |
| US6297262B1 (en) | Treatment of schizophrenia and psychosis | |
| US6358966B2 (en) | Treatment of depression | |
| MXPA06015196A (es) | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. | |
| JPH08183733A (ja) | β−アミロイドペプチドが関与する生理的障害を処置するための製剤 | |
| MXPA01002661A (en) | Treatment of depression | |
| US6262061B1 (en) | Treatment of panic attacks | |
| JP5441052B2 (ja) | アルツハイマー病治療薬 | |
| JPH1160482A (ja) | 性機能改善剤 | |
| Ohta et al. | Effects of NK-4, a cyanine dye with antioxidant activities: Attenuation of neuronal deficits in animal models of oxidative stress-mediated brain ischemia and neurodegenerative diseases | |
| WO2003006024A1 (fr) | Medicament contenant un derive de pyrimidine | |
| MXPA00009506A (en) | Treatment of panic attacks | |
| WO1997049403A1 (en) | Use of nipecotic acid or guvacine derivatives for the manufacture of a medicament for the treatment of postischemic neurodegenerative disorders | |
| JPH05262663A (ja) | 神経成長因子産生促進剤 |